Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2026 08:05 ET | Source: VivoSim Labs, Inc.

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...
February 03, 2026 07:53 ET | Source: Research and Markets

Antibody Drug Conjugates (ADC) Market Forecasts 2026-2030 with Executive and Consultant Guides - Fast-Tracking, Funding Availability, and Targeted Solutions Spurs Expansion

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Forecasts (2026-2030) by Cancer, Payload, Target, Product, User and Country/Region with Executive and Consultant...
January 29, 2026 08:00 ET | Source: Breakthru Medicine

Breakthru Medicine emerges from stealth with $60M Series A for cancer drug development

Breakthru Medicine emerges from stealth with $60M Series A in cancer drug development
January 19, 2026 04:07 ET | Source: Research and Markets

Global Antibody Drug Conjugates Market to Surge from USD 12.26 Billion in 2024 to USD 32.11 Billion by 2033

Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Size, Share & Trends Analysis Report by Application (Blood Cancer, Urothelial Carcinoma, Ovarian Cancer, Breast...
January 06, 2026 08:00 ET | Source: Biolojic Design

Biolojic Design Appoints Roger Waltzman as Chief Medical Officer

Biolojic Design Appoints Roger Waltzman as new Chief Medical Officer
November 27, 2025 09:00 ET | Source: Research and Markets

B7-H3-Targeted Immunotherapy Competitor Analysis Report 2025: More Than 15 Product Candidates are in Clinical Development, with Several Already in Clinical Phase III

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "B7-H3-Targeted Immunotherapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 27, 2025 08:56 ET | Source: Research and Markets

Folate Receptor Alpha (FRa) Targeted Therapy Competitor Analysis Report 2025: Next Generation Cell Therapy Modalities and Radiopharmaceuticals are Advancing in the Pipeline

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive...
November 27, 2025 08:45 ET | Source: Research and Markets

NaPi2b-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of NaPi2b-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 27, 2025 08:40 ET | Source: Research and Markets

Tissue Factor-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Tivdak Has Become the Benchmark for Improved Next Generation ADCs in Non-clinical and Clinical Development

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of Tissue Factor-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 24, 2025 04:06 ET | Source: Research and Markets

Rare NRG1 Fusion Market Research Report 2025-2035 | Growth Accelerates on Rising Cancer Awareness and Advances in Molecular Testing and Targeted Therapies

Dublin, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The "Rare NRG1 Fusion Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been...